The autism spectrum disorder treatment market size is estimated to be USD 2,453.2 million in 2022 and is expected to witness a CAGR of 6.47% during the forecast period 2023-2033. Rising prevalence of ASD, growing investment for ASD research and development, solid product pipelines are some of the factors contributing to the market growth. Furthermore, extensive research activities carried out by the organization and growing public knowledge of the disease and treatment alternatives are other factors supporting the market growth. However, high price of diagnosis and treatment for autism spectrum disorder and the strict laws regarding product approval is expected to hinder the growth.

Extensive research activities carried out by the organization to assess the efficacy and safety of medications in patients with ASD is expected to propel the market growth during the projected period. The strong findings of these studies present the market with novel chances for expansion. For instance, Stalicla completed successfully phase 1b trials of precision medicine candidate STP1 in March 2022, and the results were encouraging with symptom reduction in ASD patients. Therefore, it is projected that the trial’s successful conclusion and subsequent product approvals will drive the market.

Rising prevalence of ASD is predicted to fuel the market growth during the forecast period. For instance, according to a March 2022 update from the World Health Organization (WHO), one in 100 youngsters suffer from autism. In addition, a study released in October 2021 titled “Prevalence of Autism Spectrum Disorder and Co-morbidities in Children and Adolescents: A Systematic Literature Review” covered 33 papers on the prevalence of co-morbidities and included 13 studies on the prevalence of ASD. While the prevalence of ASD was between 0.38 and 1.55% in Europe, it was 1.70 and 1.85% in the United States for children aged 4 and 8, respectively. The frequency of autism spectrum disorders has also increased worldwide during the past few years, according to recent studies.

Segmentation

By Treatment

The market is categorized into selective serotonin reuptake inhibitors, antipsychotic drugs, sleep medications, stimulants, and others. In 2022, the stimulants segment accounted for the highest revenue share due to the accessibility and availability of drugs for patients. Several stimulants have been approved by the American FDA for the treatment of autistic patients, including Adderall, Dexedrine, Focalin, Vyvanse, and Ritalin. When given to patients properly, these drugs reduce their symptoms by 80%. As a result, the stimulants’ great efficacy can attract in a new target market and expand sources of income. The antipsychotic drug segment is predicted to increase profitably over the projected period. This increase can be attributed to the availability of antipsychotic medications, which are the most secure and efficient treatment option for ASD patients. Currently, the U.S. FDA has only approved Risperdal and Abilify to treat irritability in children with autism spectrum condition. Both drugs are primarily used by ASD patients owing to its high safety, efficacy, and tolerability compared to other drugs.

By Application

The market is categorized into pervasive developmental disorder, autistic disorder, asperger syndrome, and others. In the global market, the autistic disorder segment accounted for the largest revenue share in 2022 owing to disease’s rising prevalence in different regions of the world. Zynerba Pharmaceuticals estimates that there would be 1.4 million ASD patients living in the United States in November 2022. As a result, it is anticipated that there would be a greater demand for medications used to treat ASD symptoms in patients, which will help generate revenue. The others segment is anticipated to expand rapidly over the course of the forecast period. Williams Syndrome, Fragile X Syndrome, Landau-Kleffner Syndrome, Angelman Syndrome, Prader-Willi Syndrome, Rett Syndrome, and Tardive Dyskinesia are the seven primary disorders that are most closely associated with autism, according to the Autism Research Institute (ARI). 15% to 20% of people with fragile x syndrome display symptoms resembling ASD, such as hand flapping, strange gestures, and poor eye contact. The segment is therefore expected to be driven by an increase in the number of autistic patients as well as late-stage product candidates like Zygel and STX209 (Arbaclofen).

By Distribution Channel

The market is segmented into online pharmacy, hospital pharmacy, and retail pharmacy. In 2022, the retail pharmacy segment accounted for the largest revenue share owing to widespread accessibility of pharmaceuticals including stimulants, anticonvulsants, tricyclic antidepressants, SSRIs, and anxiety medications at retail pharmacies. According to a June 2021 article, between 30% and 50% of all ASD patients have reportedly received treatment with at least one of the drugs listed above. As a result, the market is greatly influenced by the growing number of people who have ASD. The hospital pharmacy industry is anticipated to increase significantly over the projection period. Increased emphasis is being paid to patient care programmes, such as the Autism Center Partial Hospital Program and Autism Inpatient Care, to help children with ASD. Rising medicine prescriptions and increasing public knowledge of the condition are further factors driving market expansion.

Regional Markets

In 2022, North America region accounted for the highest revenue in the autism spectrum disorder treatment market and is expected to maintain its dominance during the forecast period. This is attributed to the introduction and fast adoption of numerous ASD medications. It is anticipated that rising ASD research activity in the region can create new growth opportunities. For instance, in Toronto, Canada, F. Hoffmann-La Roche Ltd. started a clinical trial research in January 2020 on a novel investigational new drug Balovaptan for patients with ASD. The study’s successful conclusion is anticipated to encourage market expansion. Asia Pacific is anticipated to experience a fastest growth rate over the projection period. The industry’s presence of major players and their strategic efforts to create and market novel patient-focused solutions are attributed to the region’s development. For instance , Teijin Pharma and Hamamatsu Medical University among others confirmed the safety, effectiveness, and tolerability of oxytocin nasal spray to treat individuals with autism spectrum disorder in May 2022. Through this partnership, the Asia Pacific region will witness an increase in the study and creation of new ASD medications.

Competitor Insights

Some of the key players operating in the autism spectrum disorder treatment market are Yamo Pharmaceuticals, Bristol-Myers Squibb Company, Curemark LLC, Merck & Co., Inc., Eli Lilly and Company, Johnson & Johnson Services Inc., Novartis AG., F. Hoffman-La Roche Ltd., Pfizer Inc., Otsuka Pharmaceutical Co., Ltd., and Axial Therapeutics Inc.

• For Curemark’s CM-AT, which is approved for ASD in children aged 3 to 8, the FDA granted fast-track designation in May 2022. In addition, Indian researchers created the 6BIO molecule in November 2021. This substance has showed promise in enhancing daily activities in pre-clinical studies of patients with autism spectrum disorder.

This comprehensive research report focuses on the global and regional market size and forecasts of diverse segments including treatment, application, and distribution channel from 2023 to 2033.

Report Scope:

Segmentation: Autism Spectrum Disorder Treatment Market Report 2022 – 2033

Treatment (Revenue, USD Million), 2022 – 2033

• Selective Serotonin Reuptake Inhibitors
• Antipsychotic Drugs
• Sleep Medications
• Stimulants
• Others

Application (Revenue, USD Million), 2022 – 2033

• Pervasive Developmental Disorder
• Autistic Disorder
• Asperger Syndrome
• Others

Distribution Channel (Revenue, USD Million), 2022 – 2033

• Online Pharmacy
• Hospital Pharmacy
• Retail Pharmacy

By Region (Revenue, USD Million), 2022 – 2033

• North America
  • U.S.
  • Canada
• Europe
  • Germany
  • France
  • UK
  • Spain
  • Italy
  • Rest of Europe
• Asia Pacific
  • China
  • Japan
  • India
  • Australia
  • South Korea
  • Rest of APAC
• Latin America
  • Brazil
  • Mexico
  • Argentina
  • Rest of LATAM
• Middle East & Africa
  • South Africa
  • Saudi Arabia
  • Rest of MEA